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Abstract
One approach to improving antibiotic stewardship in primary care may be to support all Gen-
eral Practitioners (GPs) to have access to point of care C-Reactive Protein tests to guide
their prescribing decisions in patients presenting with symptoms of lower respiratory tract
infection. However, to date there has been no work to understand how clinical commission-
ing groups might approach the practicalities of system-wide implementation. We aimed to
develop an accessible service delivery modelling tool that, based on open data, could gener-
ate a layout of the geographical distribution of point of care facilities that minimised the cost
and travel distance for patients across a given region. We considered different implementa-
tion models where point of care tests were placed at either GP surgeries, pharmacies or
both. We analysed the trade-offs between cost and travel found by running the model under
different configurations and analysing the model results in four regions of England (two
urban, two rural). Our model suggests that even under assumptions of short travel distances
for patients (e.g. under 500m), it is possible to achieve a meaningful reduction in the number
of necessary point of care testing facilities to serve a region by referring some patients to be
tested at nearby GP surgeries or pharmacies. In our test cases pharmacy-led implementa-
tion models resulted in some patients having to travel long distances to obtain a test, beyond
the desired travel limits. These results indicate that an efficient implementation strategy for
point of care tests over a geographic region, potentially building on primary care networks,
might lead to significant cost reduction in equipment and associated personnel training,
maintenance and quality control costs; as well as achieving fair access to testing facilities.
Introduction
The measurement of C-Reactive Protein (CRP) at the point of care (PoC) in patients present-
ing symptoms of lower respiratory tract infections (LRTI) can support appropriate antibiotic
prescribing in primary care. A recent guideline by the National Institute for Clinical Excellence
(NICE) on pneumonia provided guidelines on prescribing based on concentration boundaries
[1].







Citation: Lamas-Fernandez C, Hayward G, Moore
M, Monks T (2019) A mathematical model for
designing networks of C-Reactive Protein point of
care testing. PLoS ONE 14(9): e0222676. https://
doi.org/10.1371/journal.pone.0222676
Editor: Andres R. Floto, Cambridge University,
UNITED KINGDOM
Received: April 29, 2019
Accepted: September 3, 2019
Published: September 17, 2019
Copyright: © 2019 Lamas-Fernandez et al. This is
an open access article distributed under the terms
of the Creative Commons Attribution License,
which permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: The code to run/
reproduce our results, plus some estimations are
available from our online repository: https://doi.
org/10.5281/zenodo.2612237. Further data needed
is available online from other sources (also linked
on the paper/appendix): Map data: https://planet.




related-data. Census data: https://www.ons.gov.uk/
peoplepopulationandcommunity/
populationandmigration/populationestimates/
There is evidence [2–5] that CRP tests can reduce the antibiotic prescribing rates for LRTI,
without affecting patient’s recovery. However, despite the evidence and availability of guide-
lines, the uptake of these techniques in England seems to be limited [6,7], especially in compar-
ison to other countries [8]. A number of barriers to widespread implementation have been
identified (such as changes to General Practitioner’s (GP) workflow or operational con-
straints), but a key barrier is the cost of machine and cartridge purchases and maintenance.
The cost of one of the testing machines considered in this study and its quality assurance costs
are £1200 and £800 per year, respectively. Quality control costs can vary depending on imple-
mentations, but can be as much as £470 per machine per year for stand-alone systems (18). If
clinical commissioning groups (CCGs) were to become responsible for the financial support
required for a system wide roll out of PoC CRP testing, it would be important to use an
approach which minimised the number of machines required, and therefore the associated
costs, without limiting patient access to testing.
In this study we aimed to provide commissioners with practical guidance on how a CRP
PoC testing network could be implemented if a decision was made to fund it. We compared
testing patients in their own GP surgeries to redirecting them to be tested at other nearby loca-
tions (pharmacies or other GP surgeries). GPs (family doctors) are the first point of contact
with the health service for the majority of patients and, therefore, GP surgeries are well distrib-
uted geographically across the country. In these shared-resource models, suspected LRTI
patients would be referred to these facilities by their usual GPs following clinical assessment, if
a CRP test was considered necessary. In a pharmacy model, patients would be issued an antibi-
otic prescription by their GP which would only be ‘cashed’ if the test result was above a
required level. The choice between these models has an impact on both commissioner
resources (the need to acquire more or less testing devices) and the patients (who might need
travel longer or shorter distances to be tested).
Aims
This study is set out to develop an automated optimisation tool that provides commissioners
with optimal tactical planning decisions (e.g. allocation of patients to testing locations) based
on a number of inputs. These inputs are based on the commissioner’s strategic decisions, for
example, whether to allow pharmacies to perform tests or not; or what is the maximum accept-
able travel distance for a patient. The main outcome measures of the model are the number of
machines required and the expected extra travel distances for patients to be tested. The results
of the model were analysed for different locations (urban and rural) and for various combina-
tions of strategic decisions.
Methods
When investigating alternative locations for PoC testing a key decision that determines the
costs and travel implications of the service delivery implementation is the quantity and physi-
cal location of PoC facilities. To determine optimal values for them under the different imple-
mentation models investigated, we developed a mathematical location-allocation model that
considers two decisions. The first one is to determine the minimum number of testing
machines needed to cover the population of the considered geographical region. The second
one is to determine their location and which patients should be assigned to them, in order to
minimise the extra travel patients might have to perform. To avoid excessive travel distances
for some patients the maximum allowed travel per patient is subject to an upper limit.
In the remainder of this section, we describe the data used for the model, the model itself,
and the different configurations we used to test the model.
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Data sources
In order to determine the layout of a CRP PoC deployment, our model requires the following
information:
• Geographical locations of GPs and pharmacies which could potentially host a CRP PoC test-
ing facility
• Testing capacity of a single machine, in number of tests per week
• Demand for tests in a census Output Area (OA), in number of tests per person and per week
• Estimations of the extra distance travelled by patients if they were receiving a test in each of
the potential testing facilities
The locations of GP surgeries (including their branches) and pharmacies are open data that
can be accessed in [9] and [10] respectively.
The testing capacity of a machine was estimated at 175 tests per week, using as a reference
the capacity of GPs for consultations. Given the uncertainty in the incidence of LRTI and the
clinician’s approach to testing, we calculated low and high estimates of demands of tests per
person and per week. We provide an analysis of the effect of using each of these estimates.
In order to take into account the geographical distribution of the population within the
considered geographical regions, we have used census Output Areas. OAs are the lowest geo-
graphical level at which the UK census provides information and are constructed with the idea
of preserving homogeneity within their population.
We refer the reader to the online appendix S1 Appendix for further details on how these
demand and capacity estimates were calculated, as well as information on the geographical
regions considered and how the GP location data can be obtained.
A central part of our modelling approach is estimating the travel burden, that is, the extra
distance that patients would need to travel to be tested in a location other than their usual GP
surgery. To compute this distance, we first calculated the base travel that patients would always
perform, even if not getting a test: the distance of a return trip from their home to their closest
GP surgery. Since this distance was not explicitly available, we approximated it as the distance
from the centroid of their origin OA to the location of the closest GP surgery. When the
patients are assigned to be tested somewhere else, their journey is extended to include this
location after leaving the GP surgery and before going home; we call this extended travel. The
travel burden is then defined as the difference between the extended travel and the base travel.
In Fig 1 we show a diagram of how these distances are defined.
The actual computations of distance were made at street level using OpenStreetMap data
[11] and the Open Source Routing Machine (OSRM) software [12]. All the distances we com-
pute were the shortest possible walking routes, as computed by OSRM. Note that, while the
2011 census data reports that 74% of the households in England and Wales have access to at
least one car [13], using walking distances provides a base measure that represents all patients.
Furthermore, since we only model extra distance, this is a suitable measure also for patients
that live relatively far from their closest GP (e.g. in rural areas) and might travel to their GPs
by public transport (e.g. bus or taxi) but would still have to walk to a testing facility.
Location-allocation model
To find the optimal location of the testing facilities and the allocations of patients to facilities,
we made use of a facility location optimisation model. Facility location is a mature field in
Operations Research [14] devoted to solving problems which involve deciding where to place
certain resource providers to cover the demand for a certain area. There exist many different
A mathematical model for designing networks of C-Reactive Protein point of care testing
PLOS ONE | https://doi.org/10.1371/journal.pone.0222676 September 17, 2019 3 / 13
variants and extensions of such models, we refer the reader to [15,16] for two literature reviews
of facility location in a health care context.
Our proposed method is an integer programming model that calculates the number of PoC
machines that should be available at each GP surgery or pharmacy location (including no
Fig 1. Schematic of the base and extended travel routes for a patient tested elsewhere than their closest GP. The travel burden is calculated as the difference of the
two.
https://doi.org/10.1371/journal.pone.0222676.g001
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machines at certain locations). The model allocates patients to one of these locations in order
to minimise the total overall travel, and ensuring that patients never have to travel more than a
predefined maximum distance, that we denote by T.
Both objectives are considered in a lexicographic order, i.e. the priority is to determine the
minimum number of machines necessary and, once this is determined, the assignments of
patients to testing locations are decided in order to minimise their travel burden, weighted by
population.
A detailed mathematical formulation of the model is given in S1 Appendix. The model was
implemented in Python and solved with Gurobi 8.0.0, see [17] for the relevant scripts.
Model configurations
In this section we describe the different configurations under which we solved the optimisa-
tion model. We identified four configuration categories: geographical location, candidate loca-
tions for placing the tests, maximum travel burden and testing demand. They are summarised
in Table 1.
For contrast, we considered two urban locations (Southampton and Oxford) and two rural
locations (Isle of Wight and Lincolnshire). These are based on the boundaries of different UK
administrative regions (eg. Unitary Authorities or Counties). In Table 2 we list some of their
key statistics, while in S1 Appendix we describe how these regions were defined in more
detail.
The base case of placing one machine at each GP surgery is represented by T = 1 m (we
allowed 1 m to avoid possible errors by the route calculation software). This setting was solved
only for GP-based facilities, as patients referred to a pharmacy would always incur in some
extra travel. Note that, even for larger values of T, imposing a maximum allowed travel burden
when we consider only pharmacies could still result in an infeasible model, particularly in
rural regions. This would happen if, for some patients, going to the nearest pharmacy is still a
burden of a distance larger than T. In these cases, to avoid infeasibility, we removed this con-
straint for these patients and assigned them to the nearest pharmacy. The percentage of
patients that are allocated within the limit set by T is reported in our results.
Patient and public involvement
The National Institute for Health Research (NIHR) Community Healthcare MedTech and In
Vitro Diagnostics Collaborative (MIC) Antimicrobial Resistance (AMR) patient and public
involvement group has been actively engaged in discussions with a member of the research
team while the study was being developed. Their views and concerns about the features of
importance to patients regarding access to CRP PoC tests have been taken into account in our
modelling approach, and they have also advised on the dissemination approach resulting in
modifications to improve the clarity of our results and conclusions.
Table 1. Summary of the factors evaluated in the different experiments of the model.
Category Levels
Region Urban, Rural
Max. travel burden (T) 1, 500, 1000, 2000 (m)
Testing demand High, Low
Candidate locations GP surgeries, Pharmacies, Both
https://doi.org/10.1371/journal.pone.0222676.t001
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Results
The following tables show the results of the optimisation model for all the combinations of the
described configurations over the two urban (Table 3) and two rural (Table 4) areas.
Differences across geographical locations
Fig 2 illustrates the required number of machines per 100,000 inhabitants and the average
travel burden for patients, for a scenario with high testing demand and using both GP surger-
ies and pharmacies as candidate locations. For the same patient travel burden, rural areas need
more testing facilities per person than urban areas. Average travel burden tends to be signifi-
cantly lower than the travel limits, as there would be only a limited number of patients are
assigned to testing facilities significantly far from their usual GP surgeries.
Table 2. Key statistics of the considered geographical regions.
Geographical Region Population Area (km2) CCGs Number of OAs
Southampton 254275 50.2 1 766
Oxford 170350 57.5 1 463
Isle of Wight 139798 382.7 1 466
Lincolnshire 1073343 6963.3 6 3422
https://doi.org/10.1371/journal.pone.0222676.t002
Table 3. Model results for urban areas. PS is the percentage of patients that can be served with the proposed maximum travel burden, T is the maximum travel burden
allowed, Mach is the number of required testing machines, ATB is the average travel burden for the patients (m) and MU (%) is the highest capacity utilisation observed
across all opened facilities, measured as the expected tests over the testing capacity of that location.
Low testing demand High testing demand
Candidate sites PS T Mach ATB MU Mach ATB MU
Southampton
GP 100 1 42 0 2.0 42 0 41.1
100 500 38 18 2.0 38 18 41.1
100 1000 32 70 2.0 32 70 41.1
100 2000 18 456 3.1 18 456 64.5
Pharmacy 65.2 500 33 464 2.0 33 464 41.2
84.4 1000 31 477 2.4 31 477 49.1
99.6 2000 17 721 2.9 17 721 60.8
Both 100 500 38 18 2.0 38 18 41.1
100 1000 31 113 2.4 31 113 49.1
100 2000 16 551 3.2 16 551 66.4
Oxford
GP 100 1 24 0 2.1 24 0 44.3
100 500 24 0 2.1 24 0 44.3
100 1000 21 63 2.2 21 63 45.8
100 2000 17 267 3.0 17 267 62.8
Pharmacy 72.7 500 23 399 2.1 23 399 44.3
91.4 1000 18 465 2.1 18 465 44.3
94.3 2000 15 497 2.3 15 497 47.4
Both 100 500 24 0 2.1 24 0 44.3
100 1000 19 179 2.2 19 179 45.8
100 2000 17 257 3.0 17 257 62.8
https://doi.org/10.1371/journal.pone.0222676.t003
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Effect of testing demand
In general, varying the testing demand estimate from low to high had negligible effect on the
number of machines required. In the Southampton, Isle of Wight and Oxford examples the
number of machines required was identical. In the low testing demand scenario, the machines
had low utilisation (the maximum utilisation was under 6%). The high testing demand sce-
nario resulted in a substantially higher utilisation of machines. The utilisation remained under
80% in all regions.
Effect of distance limit
Moving from assigning every patient to their closest GP, to allowing them to travel 500 m to
other GPs, led to reductions in the number of machines required of up to 15 machines (South-
ampton 4, Oxford 0, Lincolnshire 15, Isle of Wight 2).
The largest savings were observed when both pharmacies and GP surgeries were potential
facilities, combined with a maximum travel distance of 2000 m (with low testing demand the
machine reductions compared to the base case were: Southampton 26, Oxford 7, Lincolnshire
72, Isle of Wight 8).
The actual assignment effect of increasing the maximum travel distance allowed is illus-
trated by Fig 3 (T = 1 m) and Fig 4 (T = 2 km) for the city of Southampton, where only GP sur-
geries are considered.
Table 4. Model results for urban areas. PS is the percentage of patients that can be served with the proposed maximum travel burden, T is the maximum travel burden
allowed, Mach is the number of required testing machines, ATB is the average travel burden for the patients (m) and MU (%) is the highest capacity utilisation observed
across all opened facilities, measured as the expected tests over the testing capacity of that location.
Low testing demand High testing demand
Candidate sites PS T Mach ATB MU Mach ATB MU
Isle Of Wight
GP 100 1 26 0 1.6 26 0 33.9
100 500 24 8 1.6 24 8 33.9
100 1000 22 65 1.9 22 65 38.8
100 2000 18 316 3.1 18 316 65.4
Pharmacy 74.9 500 20 709 1.9 20 709 40.0
85 1000 20 706 1.9 20 706 40.0
90 2000 17 840 3.4 17 840 70.2
Both 100 500 24 8 1.6 24 8 33.9
100 1000 21 124 2.2 21 124 45.9
100 2000 18 316 3.1 18 316 65.4
Lincolnshire
GP 100 1 228 0 2.4 228 0 50.4
100 500 213 8 2.4 213 8 50.4
100 1000 193 38 2.7 193 38 56.6
100 2000 160 245 5.5 161 213 76.8
Pharmacy 55.4 500 132 3025 2.8 132 3025 58.1
68.7 1000 118 3044 3.1 118 3044 65.6
79.4 2000 103 3093 3.1 103 3093 65.6
Both 100 500 211 13 2.4 211 13 50.4
100 1000 188 65 2.7 188 65 56.6
100 2000 156 276 5.5 157 243 76.8
https://doi.org/10.1371/journal.pone.0222676.t004
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Note that, even in the case where all patients are allocated to be tested at their closest GP,
some surgeries do not have any machines assigned (as seen in Fig 3). This can happen if, for
every population weighted centroid of the output areas, there is another closer surgery.
Effect of allowing different candidate facilities
A pharmacy only model was unable to serve all patients under the travel restrictions for any of
the locations tested. A number of output areas have a large travel burden to access their nearest
pharmacy. This is especially relevant for rural areas (Isle of Wight 12.9 km, Lincolnshire 39.9
km), but also true in urban areas (Southampton 2.2 km, Oxford 3.7 km).
Discussion
Summary
We propose a mathematical facility location-allocation model which can be used by commis-
sioners to plan implementation layouts minimising investment and travel burden for patients.
Our results suggest that it is possible to achieve great reductions in the number of PoC
machines required to deliver this testing approach across a CCG with little travel impact for
patients. The model shows that for all regions there is a trade-off between increasing travel
requirements for patients and reducing the costs associated with testing machines. Commis-
sioners can use this model as a decision support system to guide the investment needed to roll
Fig 2. Comparison of the requirement of machines per 100k inhabitants and average travel burden for different locations and limits on travel. Results based on a
high testing demand estimate and with both GP surgeries and pharmacies as candidate locations.
https://doi.org/10.1371/journal.pone.0222676.g002
A mathematical model for designing networks of C-Reactive Protein point of care testing
PLOS ONE | https://doi.org/10.1371/journal.pone.0222676 September 17, 2019 8 / 13
out a CRP PoC testing network in an area, while ensuring the overall travel burden is
minimised.
Strengths and limitations
This study advances the literature on CRP PoC testing by considering the geographical chal-
lenges and the advantages of its widespread implementation. Our results add to previous stud-
ies that have focused on the efficiency of CRP testing and on the barriers and facilitators of its
adoption. It provides a theoretical ground for establishing service delivery models based on
operating with shared resources over a geographic region. Furthermore, it provides a practical
tool which can be used in any area to reproduce these analyses and inform practice. To facili-
tate further studies and reuse we have published all of our code online [17].
There are some limitations in the way we modelled the displacement of patients. First, we
assumed as a starting point the population weighted centroids of the OAs as provided by the
census data. In dense urban areas these are likely to be close to the inhabitants of that area, but
Fig 3. Assignment of patients to GP surgeries for the city of Southampton. Considering a high testing demand estimation and T = 1 m. Each circle represents a GP
surgery, same colour indicates assignments. Smaller grey circles indicate that no machine was allocated to that GP surgery. This assignment requires 42 machines in
total. Map data copyrighted OpenStreetMap contributors and available from https://www.openstreetmap.org.
https://doi.org/10.1371/journal.pone.0222676.g003
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in rural areas there might be a significant deviation. A clear example of this is Fig 5, where
some OAs were allocated in a counter-intuitive manner, as this was a sensible assignment for
their population weighted centroids, but possibly inadequate for some patients of the OA liv-
ing far from the population weighted centroid.
We assumed that patients would go to their closest GP, but this is not necessarily always the
case, as some people might choose to be registered somewhere else (e.g. close to their work-
place). Furthermore, our definition of travel burden does not take into account patients poten-
tially travelling to pharmacies as part of their routine and, therefore, pharmacy assignments are
always subject to travel burden (as opposed to some GP assignments). This means that we have
modelled the worst case scenario, where patients might travel to a pharmacy for a test and get a
negative result, meaning their journey did not result in the need to collect a prescription.
Nevertheless, our model considers actual walking distances and therefore takes into account
geographical features. This can be appreciated in Fig 5, where patients living in the north part
of the Isle of Wight near the Medina River were allocated across the river (e.g. the olive green
area) because there is a bridge nearby, but this assignment did not happen far from the bridge
(blue and red areas).
Fig 4. Assignment of patients to GP surgeries for the city of Southampton. Considering a high testing demand estimation and T = 2000. Each circle represents a GP
surgery, same colour indicates assignments. Smaller grey circles indicate that no machine was allocated to that GP surgery. This assignment requires 18 machines in
total. Map data copyrighted OpenStreetMap contributors and available from https://www.openstreetmap.org.
https://doi.org/10.1371/journal.pone.0222676.g004
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Finally, our model is concerned with geographical location only, and we do not take into
account the implications and costs related to recruitment of extra staff, training, disruption of
usual workflow in GP surgeries and pharmacies, etc., that would certainly be relevant if a CRP
testing network is deployed.
Comparison with existing literature
While we are not aware of similar location studies for CRP PoC tests, location problems are
common in health care, for example a location of sexual health clinics [18] or the placement of
defibrillators for cardiac arrest [19]. The latter study considers a robust model (taking into
account the uncertainty surrounding the location of cardiac arrests). We chose not to include
uncertainty as, while there is uncertainty in the demand for CRP tests, our results show that
testing capacity, even in our conservative estimates, is not a constraint driving the results of
the optimisation, as opposed to geographical location. Furthermore, the flexible nature of
deploying CRP PoC testing (as opposed, for example, to building a new hospital) makes it pos-
sible to run the model every time more data is available and reconfigure the system accordingly
(by transferring, acquiring or decommissioning equipment).
Implications for research and practice
Past research [6,7] has identified cost and clinician time as barriers against the widespread
implementation of CRP PoC. An efficient location of tests over a geographical area together
with a system where patients are referred to a testing location with delayed prescriptions may
Fig 5. Resulting assignment for the Isle of Wight, illustrating some potentially sub-optimal assignments. This
instance was solved for T = 1000, low testing demand and with facilities allowed to be located at GP surgeries
(represented by circles, coloured if used, grey if not) and pharmacies (represented by triangles, coloured if used, grey if
not). Output areas are delimited by black lines, with their population weighted centroid marked with an “x”. They are
coloured matching the colour of the PoC facility their patients have been assigned to. Map data copyrighted
OpenStreetMap contributors and available from https://www.openstreetmap.org.
https://doi.org/10.1371/journal.pone.0222676.g005
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alleviate the time pressure on GPs performing tests, as well as reduce the initial investment on
equipment and ongoing costs of machine maintenance for commissioners.
Commissioners might make use of this model to determine the budget for rolling out POC
CRP across a certain geographical area and to decide where to deploy the testing machines, for
a maximum travel burden which is considered adequate, ensuring both minimum costs and a
fair distribution of facilities. Furthermore, the results indicate that implementation models led
solely by pharmacies might greatly limit the access of some patients to CRP testing. Especially
in rural areas, the nearest pharmacy might imply a large detour for patients to be tested.
One possible avenue for future research is cost evaluation. While there is some work in the
cost [20] and cost-effectiveness of CRP PoC testing [21], we are not aware of an analysis that
takes into account different implementation models for entire geographic areas testing net-
work. Our results might provide more information on the cost-effectiveness of CRP testing
over a wider area.
In England, our models are highly relevant to the recently announced NHS primary care
networks [22]. These are groups of general practices based in areas with populations ranging
from 30,000 to 50,000. Their focus is to enhance the collaboration between health care services
in the area and, therefore, the network model could provide the infrastructure needed to share
medical records, booking systems, administrative costs and testing results where POC
machines are placed in a limited number of practices. Planning tools such as ours could sup-
port the distribution of limited funds for point of care testing in order to ensure fair and equi-
table access for patients and their families.
More widely, the model might be applicable in any region where population estimates are
available with sufficiently small granularity (such as in the case of output areas). It could also
consider other type of facilities that might be suitable for POC testing (hospitals, for example),
or other types of POC tests.
Supporting information
S1 Appendix. Online appendix. Also available at [17].
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